Figma Shares Indicated To Open $105/$110
Lexaria Bioscience Corp. (NASDAQ: NASDAQ:LEXX), a micro-cap company with a market value of $17.35 million, saw its Chief Executive Officer Christopher Richard purchase 15,000 common shares on July 29, 2025, at $0.9094 per share, totaling $13,641. The purchase comes as the stock trades near its 52-week low of $0.79, having declined over 57% year-to-date. InvestingPro analysis suggests the stock is currently undervalued, with additional insights available through their comprehensive financial analysis platform.
Following the transaction, Richard directly owns 65,000 common shares of Lexaria Bioscience.
Richard also holds options to purchase 350,000 common shares. This includes options for 200,000 shares with an exercise price of $3.92, expiring on August 31, 2029, and options for 150,000 shares with an exercise price of $1.04, expiring on May 15, 2030.
In other recent news, Lexaria Bioscience has made several noteworthy announcements. The company reported interim results from its Phase 1b GLP-1-H24-4 study in Australia, focusing on the DehydraTECH-semaglutide and DehydraTECH-tirzepatide arms. These developments come alongside Lexaria’s announcement of two new international patents, expanding its patent portfolio to a total of 50, including a patent in Australia for epilepsy treatment. H.C. Wainwright has adjusted its price target for Lexaria Bioscience, lowering it from $5.00 to $4.00, while maintaining a Buy rating. This adjustment follows positive partial results from a human pilot study comparing DehydraTECH-processed liraglutide with the conventional Saxenda injection.
Moreover, Lexaria’s DehydraTECH technology has shown potential in reducing side effects in GLP-1 weight loss and diabetes drugs, addressing a significant issue in patient retention. The company is also advancing its drug delivery technology through a collaboration with PharmaCO, with pre-clinical studies completed under a Material Transfer Agreement. PharmaCO is interested in further data from Lexaria’s ongoing human study, which could lead to additional collaborative clinical studies. These developments highlight Lexaria’s continued efforts in expanding its technological capabilities and market presence.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.